A new IMS Health report indicates the loss of patents by top-selling brand drugs during the period 2011 to 2014 may bring $70 billion in savings to the marketplace.  Among the brand drugs that will soon face generic competition are the following:

  • Pfizer’s cholesterol-reducing drug Lipitor
  • Bristol’s and Sanofi’s blood-clot preventer Plavix
  • Lilly’s schizophrenia drug Zyprexa
  • Merck’s asthma treatment Singulair

To learn more about IMS Health’s report, read this article.

And don’t forget — unless you change your PBM contract terms to ensure that you — not your PBM — will realize the financial benefits from newly available generic drugs, you may never obtain your rightful savings.  Read the articles under Topics 3 and 5 on our Videos and Articles page, and learn exactly what you need to do.